Thus, the immunomodulatory nature of VA raises the question of whether there are immunologic interactions between VA and inhibitors of the PD-1/PDL-1 or CTLA-4 pathways that might lead to increased toxicity for cancer patients. This evidence concerns the gene PDCD1 and cancer.